Next Generation News and Research

RSS

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP program recognized Quanterix's Single Molecule Array (SiMoA™) platform as a promising advance that will improve diagnosis and treatment of disease while reducing healthcare costs.

3 Nov 2010

NanoString’s nCounter CNV CodeSets help detect genetic copy number variations

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced the launch of a novel solution for detecting genetic copy number variations (CNVs) associated with disease susceptibility, drug response and cancer progression.

From NanoString Technologies 2 Nov 2010

RTI third quarter net loss increases to $16.8 million

RTI International Metals, Inc.,, released results today for the third quarter of 2010.

2 Nov 2010

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Rubicon Genomics today reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing (NGS).

2 Nov 2010

Cato Research selects BioClinica's clinical trial management system

BioClinica®, Inc.,, a global provider of clinical trial management solutions, today announced a new agreement with Cato Research Ltd., a full-service contract research organization. Cato Research selected BioClinica's clinical trial management system (CTMS) platform in its search for a best-in-class solution to better serve its growing worldwide client base.

From Clario 1 Nov 2010

Life Technologies announces launch of new sequencer to deliver genomic data

Life Technologies Corporation a provider of innovative life science solutions, today announced the launch of the 5500xl SOLiD Sequencer, a new instrument designed to deliver the industry's fastest and most accurate genomic data for cancer biology and genetic disease research.

1 Nov 2010

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

Labtec GmbH, Langenfeld, Germany announces the start of the phase II clinical development program for its sufentanil transdermal patch. The multicentric, randomized, open label study will evaluate efficacy and safety of Sufentanil TDS against standard treatment in patients with chronic cancer pain.

1 Nov 2010

New nanoparticle deodorant has antibacterial and anti-odor properties

Scientists are reporting development of a new approach for dealing with offensive household and other odors one that doesn't simply mask odors like today's room fresheners, but eliminates them at the source. Their research found that a deodorant made from nanoparticles hundreds of times smaller than peach fuzz eliminates odors up to twice as effectively as today's gold standard.

30 Oct 2010

ADA apologizes for not strongly enforcing non-discriminatory membership practices

The American Dental Association (ADA) acknowledged today that it deeply regrets not taking a stronger stand against discriminatory membership practices during the pre-civil rights era.

30 Oct 2010

KAST trial to assess Kiva vertebral augmentation treatment for painful VCFs due to osteoporosis

Physicians at The Medical College of Wisconsin are conducting the KAST clinical trial at Froedtert Hospital to assess the safety and effectiveness of a new vertebral augmentation treatment (Kiva) for painful vertebral compression fractures (VCFs) due to osteoporosis.

29 Oct 2010

New wearable wireless sensors can improve healthcare

Members of the public could form the backbone of powerful new mobile internet networks by carrying wearable sensors. According to researchers from Queen's University Belfast, the novel sensors could create new ultra high bandwidth mobile internet infrastructures and reduce the density of mobile phone base stations.

29 Oct 2010

Boston Scientific's Neurovascular business to be acquired by Stryker

Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months.

From Stryker 29 Oct 2010

Talecris third quarter net revenue increases 2.8% to $407.0 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three and nine months ended September 30, 2010 and filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Oct 2010

Stryker enters agreement to acquire assets of Neurovascular division of Boston Scientific

Stryker Corporation announced today a definitive agreement to acquire the assets of the Neurovascular division of Boston Scientific in an all cash transaction for $1.5 billion, which includes $100 million of milestone payments.

From Stryker 29 Oct 2010

IntriCon third quarter net sales increases 14% to $14.7 million

IntriCon Corporation a designer, developer, manufacturer and distributor of body-worn medical devices, today announced financial results for its third quarter ended September 30, 2010.

29 Oct 2010

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

Caliper Life Sciences, Inc., today reported results for its third quarter ended September 30, 2010. Third quarter GAAP revenue decreased 8% to $29.7 million from $32.2 million in the same period in 2009 as a result of divestitures in 2010 and 2009. Revenue from on-going business increased 10% on a reported basis and 11% on an organic basis.

28 Oct 2010

NeoGenomics third quarter revenue grows 19% to $8.7 million

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the third quarter 2010.

28 Oct 2010

PCP credits dedicated primary care community for formation of Harvard's new Center

Harvard Medical School's (HMS) establishment of its $30 million Center for Primary Care is a powerful statement of the importance of primary care and the role major medical institutions must play in its transformation, according to Boston-based nonprofit Primary Care Progress (PCP). PCP credits a dedicated and engaged primary care community, partnering with a visionary dean, for the formation of Harvard's new Center.

28 Oct 2010

Next Generation News and Research

Immunomedics product candidates, technologies receive recognition from QTDP program

Quanterix granted $733,437 under QTDP program for Single Molecule Array platform

NanoString’s nCounter CNV CodeSets help detect genetic copy number variations

RTI third quarter net loss increases to $16.8 million

Rubicon's PicoPlex kits provide DNA methylation profiling using next-generation sequencing

Cato Research selects BioClinica's clinical trial management system

Life Technologies announces launch of new sequencer to deliver genomic data

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Labtec initiates Sufentanil TDS phase II clinical development program for chronic cancer pain

New nanoparticle deodorant has antibacterial and anti-odor properties

ADA apologizes for not strongly enforcing non-discriminatory membership practices

KAST trial to assess Kiva vertebral augmentation treatment for painful VCFs due to osteoporosis

New wearable wireless sensors can improve healthcare

Boston Scientific's Neurovascular business to be acquired by Stryker

Talecris third quarter net revenue increases 2.8% to $407.0 million

Stryker enters agreement to acquire assets of Neurovascular division of Boston Scientific

IntriCon third quarter net sales increases 14% to $14.7 million

Caliper Life Sciences third quarter GAAP revenue decreases 8% to $29.7 million

NeoGenomics third quarter revenue grows 19% to $8.7 million

PCP credits dedicated primary care community for formation of Harvard's new Center

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News